Heart scarring over time: new study aims to predict sudden death risk in HCM patients

NCT ID NCT07054073

Recruiting now Knowledge-focused Sponsor: Christopher Kramer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up on people with hypertrophic cardiomyopathy (HCM), a genetic condition that thickens the heart muscle. Researchers want to see how scarring in the heart (called late gadolinium enhancement, or LGE) changes over at least 7 years and whether it predicts serious problems like sudden cardiac arrest or heart failure. About 314 participants from an earlier study will get repeat MRI scans to track these changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY (HCM)

Contacts and locations

Locations

Brigham & Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Cleveland Clinic
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
London Chest Hospital
NOT_YET_RECRUITING

London, E2 9JX, United Kingdom
Northwestern
NOT_YET_RECRUITING

Evanston, Illinois, 60208, United States
Tufts Medical Center
NOT_YET_RECRUITING

Medford, Massachusetts, 02155, United States
University Hospitals Birmingham NHS Foundation Trust
NOT_YET_RECRUITING

Birmingham, B15 2GW, United Kingdom
University of Michigan
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.